Protara Therapeutics (TARA) risk factors, FY2025 10-K

Risks Related to Our Financial Condition

1. 01We have a limited operating history and have never generated any revenues
2. 02We expect to incur significant expenses and significant losses for the foreseeable future and may never generate revenue or achieve or maintain profitability
3. 03We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all34% rewritten
4. 04Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited23% rewritten
5. 05The April 2024 Common Warrants are speculative in nature47% rewritten

Risks Related to Drug/Biologics Development and Commercialization

1. 06Our business depends on the successful preclinical and clinical development, regulatory approval and commercialization of our product candidates, including TARA-002 and IV Choline Chloride
2. 07If any one of these factors is not present, many of which are beyond our control, we could experience significant delays or an inability to obtain regulatory approval of our product candidates, including TARA-002 or IV Choline Chloride
3. 08We have never completed a registrational clinical trial or made a BLA or NDA submission and may be unable to successfully do so for TARA-002 or IV Choline Chloride41% rewritten
4. 09Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of adoption and use necessary for commercial success
5. 10Preclinical and clinical development involves lengthy and expensive processes with uncertain outcomes. We may incur additional expenses or experience delays in completing, or ultimately be unable to complete, the development of our current product candidates or any future product candidates
6. 11Interim, topline and preliminary data from our clinical trials may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data
7. 12The clinical development of our product candidates has included and may continue to include clinical trial sites outside the U.S., and the FDA and applicable foreign regulatory authorities may not accept data from such sites22% rewritten
8. 13TARA-002 is an immunopotentiator, and one indication that we are pursuing is the treatment of LMs. There are no FDA-approved therapies for the treatment of LMs and it is difficult to predict the timing and costs of clinical development for TARA-002 for LMs
9. 14Certain disorders we seek to treat have low incidence and prevalence, and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our clinical trials or slower commercial revenue if approved
10. 15Our product candidates may cause undesirable or unforeseen side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action
11. 16A Fast Track Designation by the FDA may not lead to a faster development or regulatory review or approval process45% rewritten
12. 17An Orphan Drug Designation by the FDA or European Commission does not increase the likelihood that our product candidates will receive marketing exclusivity24% rewritten
13. 18A Breakthrough Therapy Designation by the FDA may not lead to a faster development or regulatory review or approval process24% rewritten
14. 19Although the FDA has granted Rare Pediatric Disease Designation for TARA-002 for the treatment of LMs, a BLA for TARA-002, if approved, may not meet the eligibility criteria for a PRV44% rewritten
15. 20Any adverse developments that occur in patients undergoing treatment with OK-432 / Picibanil or in patients participating in clinical trials conducted by third parties may affect our ability to obtain regulatory approval or commercialize TARA-002
16. 21We may choose to delay or discontinue developing or commercializing any of our product candidates at any time during development or after approval, which would reduce or eliminate the potential return on investment for those product candidates
17. 22Our product candidates, if approved, will face significant competition and their failure to compete effectively may prevent them from achieving significant market penetration
18. 23We currently have limited marketing capabilities and no sales organization. If we are unable to grow our sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue
19. 24TARA-002 and any future product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
20. 25We have only received the exclusive rights to the materials required to commercialize TARA-002 in territories other than Japan and Taiwan until June 17, 2030, or an earlier date if Chugai Pharmaceutical terminates the agreement with us for any number of reasons, following which such rights become non-exclusive69% rewritten
21. 26We face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate
22. 27Our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs and any partners with whom we may collaborate may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
23. 28We may be subject to risks related to off-label use of our product candidates, if approved
24. 29If we or any partners with which we may collaborate are unable to achieve and maintain coverage and adequate levels of reimbursement for TARA-002 or IV Choline Chloride following regulatory approval, their commercial success may be hindered severely
25. 30Healthcare reform measures could hinder or prevent the commercial success of our product candidates28% rewritten
26. 31We are subject to strict healthcare laws, regulation and enforcement, and our failure to comply with those laws could adversely affect our business, operations and financial condition
27. 32We may in-license and acquire product candidates and may engage in other strategic transactions, which could impact our liquidity, increase our expenses and present significant distractions to our management
28. 33Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business
29. 34We expect to rely on agreements with third parties for the successful development and commercialization of our product candidates
30. 35We cannot assure you that we will be able to establish or maintain third-party relationships in order to successfully develop and commercialize our product candidates
31. 36Our CDMOs and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly
32. 37Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
33. 38If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan
34. 39The effects of epidemics and pandemics and their corresponding macroeconomic impacts could materially and adversely impact our business, including our clinical development plans and non-clinical research

Risks Related to Our Common Stock

1. 40We expect our stock price to be highly volatile
2. 41Moreover, the stock markets in general have experienced substantial volatility in our industry that has often been unrelated to the operating performance of individual companies or a certain industry segment. These broad market fluctuations may also adversely affect the trading price of our shares
3. 42We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies
4. 43If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline
5. 44We are able to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors
6. 45We do not anticipate paying any dividends in the foreseeable future
7. 46If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline85% rewritten

Risk Related to Our Ownership Structure and Governance

1. 47Certain stockholders have the ability to control or significantly influence certain matters submitted to our stockholders for approval
2. 48Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our business more difficult and may prevent attempts by our stockholders to replace or remove management
3. 49Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees

Risks Related to Intellectual Property Rights

1. 50We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us
2. 51We may not be able to protect our intellectual property rights throughout the world
3. 52Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
4. 53If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates
5. 54We may be subject to claims that our officers, directors, employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers